#336 ASA in TKA and THA Patients: Back to the future for VTE prophylaxis?
CLINICAL QUESTION
For total knee (TKA) or hip arthroplasty (THA) patients, does ASA result in similar symptomatic venous thromboembolism (VTE) and bleeding rates as low molecular weight heparins (LMWHs) or direct-acting oral anticoagulants (DOACs)?
BOTTOM LINE
After initial treatment with 10-days of LMWHs or 5-days of DOACs, switching to ASA results in similar VTE and bleeding rates. Starting ASA alone immediately after surgery results in more VTEs (3.5% versus 1.8%) than LMWH. Due to cost and ease of use, after initial treatment with LMWHs or DOACs, patients can transition to ASA for the remainder of their VTE prophylaxis.
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
EVIDENCE
- From three publicly funded, non-inferiority randomized controlled trials. Only symptomatic VTEs reported.
- After initial treatment with anti-coagulants:
- ASA versus LMWH:1 778 Canadian THA patients; received dalteparin for 10 days then randomized to dalteparin or ASA 81mg daily for another 28 days. Study terminated early due to recruitment challenges. At 3 months:
- Symptomatic VTE, major and relevant non-major bleeding: Not statistically different.
- ASA versus DOAC:2 3424 Canadian THA/TKA patients; received rivaroxaban for 5 days then randomized to rivaroxaban or ASA 81mg daily for 9 (knee) or 30 (hip) additional days. At 3 months:
- Symptomatic VTE, major and relevant non-major bleeding: Not statistically different.
- ASA versus LMWH immediately after surgery:3
- 9711 Australian TKA/THA patients randomized to ASA 100mg daily or enoxaparin 40mg/day for 14 (knee) or 35 (hip) days. Study stopped early for LMWH superiority. At 90 days:
- Symptomatic VTE: ASA 3.5% versus enoxaparin 1.8%, statistically different.
- Major bleeding, all-cause mortality: No difference.
- 9711 Australian TKA/THA patients randomized to ASA 100mg daily or enoxaparin 40mg/day for 14 (knee) or 35 (hip) days. Study stopped early for LMWH superiority. At 90 days:
- ASA versus LMWH:1 778 Canadian THA patients; received dalteparin for 10 days then randomized to dalteparin or ASA 81mg daily for another 28 days. Study terminated early due to recruitment challenges. At 3 months:
- Without prophylaxis, ~4% of arthroplasty patients will develop a symptomatic VTE.4
- Guidelines recommend anticoagulation for 14 (knee) and 35 (hip) days with one of LMWH, DOAC, Vitamin K antagonist, or ASA.4,5
- Medication Cost (30 days):6
- LMWH: $200-300
- DOAC: $50-100
- ASA: $5
Latest Tools for Practice
#378 Tony Romo-sozumab: Winning touchdown in osteoporosis or interception for the loss?
What is the efficacy and safety of romosozumab in postmenopausal women with osteoporosis?
#377 How to slow the flow IV: Combined oral contraceptives
In premenopausal heavy menstrual bleeding due to benign etiology, do combined oral contraceptives (COC) improve patient outcomes?
#376 Testosterone supplementation for cis-gender men: Let’s (andro-)pause for a moment (Update)
What are the benefits and harms of testosterone supplementation in healthy cis-gender men or those with age-related low testosterone?
Useful
interesting article, will make me more confident to recommend asa following joint replacement after initial treatment with LMWH or DOAC
ASA following initially DOAC is as effective in preventing DVT for postsurgical hip or knee replacement
Useful
Good review
helpful
Very helpful
It would be more comfortable for the parents as well
Very cost effective
What does of ASA?
ASA dose?